21 results about "Advanced cancer" patented technology

The application discloses a kind of intelligent service systems of advanced cancer pain pain, including: analgesic device, massage piece, driving source and ice piece, ice piece is located inside the mounting seat side surface, ice piece is used to contact cooling massage ball;Push module is used to daily push the predetermined check quantization table to patient, check quantization table at least includes one or more of the following each item: diet condition, sleep condition, body pain condition, self cognitive ability and mental state;Evaluation module, evaluation module obtains patient state evaluation result according to the data of patient to check quantization table, and according to evaluation result, push management scheme to patient and adjust analgesic device analgesic scheme, the living condition of patient every day is obtained regularly by push module, and the individualized, centralized pain intervention scheme is formed by evaluation module, one aspect realizes the timely evaluation of patient life quality, while quantized mode is convenient for others to view specific change situation, to improve specific condition of patient in a targeted manner.

The present invention provides a process and method for the early detection and diagnosis of disease by reading and decoding volatile organic compounds (VOCs) for signatures associated with a specific disease. Urine is available as a diagnostic sample providing its off gas with VOCs for rapid screening from its outset, each disease begins producing its own unique set of volatile organic compounds. For many diseases, this early-stage detection may be many months or years before noticeable symptoms. The VOC emissions when analyzed, result in a “signature” that identifies and distinguishes the developing, or at later stages, the developed disease. The device assays non-invasively obtained biosamples in real-time to output a VOC based signature that, when correlated with data in a disease signature library, identifies one or more diseases associated with the sample.

The present invention is suitable for the technical field of plant extraction and separation, and provides a polysaccharide compound having a definite molecular structure. The polysaccharide compound is suitable for treatment of patients suffering from advanced cancers (no longer satisfying the operation condition, only three to six months of survival time being left, but still satisfying the chemotherapeutic condition). The present invention comprises: S1, carrying out dust removal on Ganoderma lucidum, drying same and crushing same; S2, putting same into a closed container, mixing same with water, and performing high-temperature and high-pressure extraction to obtain a pharmaceutical effect ingredient; S3, removing dregs form an extracted concentrated liquid containing the pharmaceutical effect ingredient; and S4, preparing the dreg-removed concentrated liquid into a solution having a certain concentration, and performing column chromatography separation to obtain the pharmaceutical effect ingredient a polysaccharide. The pharmaceutical effect ingredient polysaccharide has good water solubility and is easy to absorb by the human body, has an anti-tumor pharmaceutical effect, and has an effect of preventing tumorigenesis for humans. Especially, during use in combination with chemotherapeutic drugs, the polysaccharide can eliminate the toxic and side effects of the chemotherapeutic drugs on the human body, and control and reduce tumor lumps and reduce and kill tumor cells, which are all proved by corresponding experimental data.

The invention discloses a humanized antibody targeting DLL3 and an application of the humanized antibody. The amino acid sequence of a heavy chain variable region of the antibody is designed to be any one shown in SEQ ID NO: 1-SEQ ID NO: 9, the amino acid sequence of a light chain variable region of the antibody is designed to be any one shown in SEQ ID NO: 10-SEQ ID NO: 18, and the amino acid sequence of any heavy chain variable region and the amino acid sequence of any light chain variable region are paired and combined in pairs. The humanized antibody targeting the DLL3 target spot has strong persistence and immune memory, can survive in a body for a long time, continuously monitors and removes residual or recurrent tumor cells, reduces the recurrence risk, mainly aims at advanced cancer patients, has obvious killing effect on lung cancer tumors, and has a good clinical effect on treatment of advanced cancers.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity / weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory / autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound having a clear molecular structure and an anti-tumor effect. The polysaccharide compound is used for the treatment of patients with advanced cancers (patients who have lost surgical conditions, have a survival time of only three to six months, and are still eligible for chemotherapy), and has a molecular formula of: (C30H50O25)n. The active ingredient of Ganoderma is extracted under high temperature and high pressure to obtain the pharmacophore polysaccharide, i.e., the polysaccharide compound. The polysaccharide having the pharmacophore has good water solubility, is easily absorbed by a human body, has an anti-tumor efficacy, and is capable of preventing human tumorigenesis. Particularly, when being used in combination with a chemotherapeutic drug, the polysaccharide can eliminate toxic side effects on a human body caused by the chemotherapeutic drug, control and reduce the tumor mass, and reduce and eliminate tumor cells, which effects are all supported by corresponding experimental data.

FIELD: anesthesiology; resuscitation.SUBSTANCE: following is determined before surgery: risk of surgery, presence of coronary heart disease, presence of cancer, presence of advanced cancer, and duration of voluntary threshold apnea in seconds. The risk of developing postoperative intestinal paresis is determined using an original formula.EFFECT: preoperative prediction of the development of intestinal paresis after abdominal surgery.1 cl, 2 tbl, 2 ex

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound GLP-4 that has a clear molecular structure and has the effects of treating emphysema and pulmonary fibrosis and resisting tumors, which polysaccharide compound has a molecular formula of: (C162H270O135)n. Ganoderma is subjected to high-temperature and high-pressure extraction using an alkali solution, the resulting medicine residues are extracted, and then separation is performed by column chromatography to obtain the polysaccharide compound. The polysaccharide compound has a good water solubility, is easily absorbed by a human body, has better effects than pirfenidone in terms of the treatment of emphysema and pulmonary fibrosis, and also has efficacy in patients with advanced cancers (patients who have lost surgical condition, have a survival time of only three to six months, and still have chemotherapy condition). Especially when being used in combination with a chemotherapeutic drug, the polysaccharide compound can eliminate the toxic side effects caused by the chemotherapeutic drug in the human body, and can be used for controlling and reducing a tumor mass, and reducing and eliminating tumor cells, which effects are all supported by corresponding experimental data.

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound GLP-4 that has a clear molecular structure and has the effects of treating emphysema and pulmonary fibrosis and resisting tumors, which polysaccharide compound has a molecular formula of: (C162H270O135)n. Ganoderma is subjected to high-temperature and high-pressure extraction using an alkali solution, the resulting medicine residues are extracted, and then separation is performed by column chromatography to obtain the polysaccharide compound. The polysaccharide compound has a good water solubility, is easily absorbed by a human body, has better effects than pirfenidone in terms of the treatment of emphysema and pulmonary fibrosis, and also has efficacy in patients with advanced cancers (patients who have lost surgical condition, have a survival time of only three to six months, and still have chemotherapy condition). Especially when being used in combination with a chemotherapeutic drug, the polysaccharide compound can eliminate the toxic side effects caused by the chemotherapeutic drug in the human body, and can be used for controlling and reducing a tumor mass, and reducing and eliminating tumor cells, which effects are all supported by corresponding experimental data.

The present application relates to the field of tumor organoids and personalized medicine screening, and particularly relates to a tumor-like tissue construction and drug sensitivity testing method based on circulating tumor cells. The present application collects various cells through gradient centrifugation and annular microfluidic sorting, and then establishes a standardized method for separating, screening and culturing multi-cell subtype tumor-like tissues through self-made materials and culture solution. This method is universal, and the obtained tumor-like tissue contains at least circulating tumor cells, tumor stem cells, macrophages and other multi-cell subtypes. The personalized drug sensitivity test can be performed within two weeks of obtaining the patient's peripheral blood. After drug screening and clinical data comparison, the consistency of the present application and the actual drug use of the patient reaches more than 80%. Compared with the prior art, the present application has the advantages of rapidity, cheapness and accuracy, and can save the time and risk of the patient's drug trial, and has great clinical significance in personalized tumor drug guidance, especially for patients with advanced cancer.

Opioid receptor agonists, with morphine being a representative example, are the most widely used, powerful analgesics in clinical practice. These drugs effectively relieve pain, particularly postoperative pain and pain associated with advanced cancer. However, opioid use can easily lead to tolerance and hyperalgesia, often developing within a week. Once tolerance and hyperalgesia develop, the dose must be continuously increased to maintain the analgesic effect. This means that the body requires larger doses of the drug to achieve the same analgesic effect as the initial dose. Higher doses, however, can lead to more severe hyperalgesia, tolerance, constipation, addiction, and respiratory depression. Cobra neurotoxin peptides can both inhibit the hyperalgesia and tolerance associated with opioids and enhance their efficacy. When used in combination with opioids, they enable the latter to achieve analgesia at lower doses without developing tolerance and hyperalgesia, thus resolving the clinical challenge of long-term opioid use.

The invention relates to medical uses of a compound of general formula (I), (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2, which can be the same group or a different group, are independently a hydroxy group or a methoxy group or, taken together, a methylenedioxy group, R3 and R4, which can be the same group or a different group, are independently a hydroxy group or a methoxy group, R5 is phenyl group, and R6 is a phenyl group, wherein said phenyl groups are independently optionally substituted, and wherein n is 2, and to pharmaceutical compositions comprising said compound of general formula (I), for use in the treatment of cancer in a human subject, wherein said compound of general formula (I) is administered in a therapeutically effective dose to said human subject. The invention is also related to medical uses of pharmaceutical compositions comprising said compound of general formula (I) or said pharmaceutically acceptable salt thereof.

The present application is suitable for the technical field of plant extraction and separation, and provides a polysaccharide compound with clear molecular structure, which is suitable for treating patients with advanced cancer (surgical conditions have been lost, survival time is only three to six months, and chemotherapy conditions are still available), comprising: S1, drying and crushing Ganoderma lucidum; S2, mixing with water in a sealed container to extract effective components under high temperature and high pressure; S3, removing residues from the concentrated liquid with effective components; and S4, preparing the residue-removed concentrated liquid into a certain concentration to obtain polysaccharide with effective components through column chromatography. The polysaccharide with effective components has good water-soluble performance, is easy to be absorbed by the human body, has antitumor efficacy, and has efficacy in preventing the occurrence of tumors in humans, especially when used in combination with chemotherapy drugs, the toxic and side effects of the chemotherapy drugs on the human body can be eliminated, and the control, reduction, and elimination of tumor cells are all supported by corresponding experimental data.

The invention discloses a telomere Plus compound which is prepared by the following steps: step 1, preparing an extraction composition used by the telomere Plus compound from the following raw materials in parts by weight: 6-10 parts of green soy beans, 6-10 parts of broccoli, 6-10 parts of cabbages, 4-8 parts of cucumbers, 8-12 parts of avocados, 5-9 parts of avocados, 8-12 parts of mushrooms, 3-7 parts of tomatoes, 3-7 parts of hedyotis diffusa and 5-9 parts of peanuts; and 9-13 parts of grapes. The preparation method has the beneficial effects that the telomere concentrated essence from a natural fermentation extraction source is adopted, an international patent membrane carrier formula is applied to quickly and powerfully absorb to form a complex, and a targeted biological liposome carrier technology is applied to prepare the telomere Plus compound, so that the defects of the traditional plant extraction telomere enzyme are well overcome, and the preparation method is simple and convenient. The detention time of the telomere Plus compound in the body of a patient can be prolonged, so that the treatment effect is improved, the toxic and side effects are reduced, and meanwhile, the pain of a patient with advanced cancer in the treatment process is remarkably reduced.

This invention relates to the fields of medical data processing and multimodal emotion computing, and discloses an emotion state recognition system for vocal micro-expressions in patients with advanced cancer. The system constructs a temporal state vector reflecting the patient's neural control ability by calculating the neural conduction lag rate and the physiological vocal energy index. A state-adaptive gating module generates a confidence mask to weight the multimodal features. Subsequently, an emotion decoupling and reconstruction module uses manifold orthogonal projection to separate the weighted features into physiological harm perception components and psychological emotional response components, and combines sparse dictionary reconstruction to remove noise. Finally, a fusion decision and grading module combines a temporal convolutional network with an adaptive threshold calibration mechanism based on the energy index to output pain grading results and decision signals. This invention can effectively distinguish between a patient's subjective masking and physiological exhaustion state, decouple the physical and psychological attributes of pain, and avoid missed detections due to weak reactions.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity / weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory / autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

An oncolytic virus for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patients with no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / or cancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus: is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

This invention discloses a massage and relaxation device for palliative care of elderly patients with advanced cancer, comprising a base, a support plate, a placement plate, and a cloth. A connecting plate is attached to the top right side of the base, the cloth is woven into the middle of the connecting plate, the placement plate is attached to the connecting plate, and the support plate is rotatably connected to the placement plate via a rotating shaft. It also includes an upper limb massage mechanism, with the support plate equipped with an automatic upper limb massage mechanism for massaging the elderly patient's upper limbs. This invention uses a power component to drive a large gear and a small gear transmission, thereby rotating the massage stick to massage the elderly patient's upper limbs, thus achieving automatic massage of the elderly patient's upper limbs, making operation effortless and convenient.

The present invention is applicable to the technical field of plant extraction and separation. Provided is a polysaccharide compound that has a clear molecular structure and an anti-tumor efficacy and that can eliminate toxic side effects of chemotherapy. The polysaccharide compound is used for the treatment of patients with advanced cancers (patients who have lost surgical conditions, have a survival time of only three to six months, and are still eligible for chemotherapy). The molecular formula of the polysaccharide compound is: (C66H110O55)n. The active ingredient of Ganoderma is extracted under high temperature and high pressure to obtain the pharmacophore polysaccharide, i.e., the polysaccharide compound. The polysaccharide having the pharmacophore has good water solubility, is easily absorbed by a human body, has an anti-tumor efficacy, and is capable of preventing human tumorigenesis. Particularly, when being used in combination with a chemotherapeutic drug, the polysaccharide can eliminate toxic side effects on a human body caused by the chemotherapeutic drug, control and reduce the tumor mass, and reduce and eliminate tumor cells, which effects are all supported by corresponding experimental data.

This invention pertains to the field of plant extraction and separation technology, and provides a polysaccharide compound with a defined molecular structure that possesses antitumor efficacy. The polysaccharide compound is intended for the treatment of advanced cancer patients (those who are no longer candidates for surgery, have a life expectancy of only three to six months, and are still eligible for chemotherapy). The molecular formula is: (C30H50O25)n. The active ingredient, polysaccharide, is obtained through the extraction of effective components from Ganoderma lucidum under high temperature and high pressure. The polysaccharide with this active ingredient, characterized by its water solubility, is readily absorbed by the human body, offers antitumor effects, and has proven efficacy in the prevention of tumor development in humans.

The invention belongs to the field of medicine research and development, and in order to solve the clinical oncology problem of depression of advanced cancer patients, a novel prodrug is developed, and the depression symptom is improved while cancer cells are targeted. The prodrug is a prodrug of PCPA and venlafaxine and shows effective binding affinity with human LSD 1 enzyme, and the LSD 1 enzyme is a biomarker and is also a molecular target for cancer treatment. An in-vitro research shows that the prodrug effectively occupies a PCPA binding site in the LSD 1 protein, and shows a strong inhibition effect on the proliferation of MDA-MB-231. In-vivo studies show that the previous dosage reduces the immobility time in a mouse tail suspension test in a dependent manner, and compared with the desvenlafaxine succinate (DVS), the desvenlafaxine succinate has a higher curative effect. The prodrug has dual functions: as a novel triple reuptake inhibitor, the prodrug can effectively relieve depressive symptoms, and as an LSD 1 inhibitor, the prodrug plays a role and shows an anti-cancer characteristic.